Dataset Information

Valproic acid inhibits Burkitt lymphoma by downregulating PFN2 expression to modulate the PI3K/AKT pathway

ABSTRACT: Burkitt lymphoma (BL) is a type of B-cell non-Hodgkin's lymphoma, which commonly occurs in children. At present, chemotherapy is the main treatment for BL, but CHOP treatment regimen has limited effectiveness, requiring precautions against central nervous system involvement and tumor lysis syndrome. Therefore, it is urgent and necessary to find effective and low toxic drugs for the treatment of BL. Valproic acid (VPA), a commercial antiepileptic drug, has been reported to have an inhibitory effect in some tumors, but whether it is effective against BL is unclear. Using CCK-8 test and flow cytometry analysis, we found that VPA could inhibit the proliferation, cell cycle, and promote apoptosis of BL cell lines (Daudi, Raji and Namalwa). Moreover, VPA had a significant inhibitory effect on Namalwa cell line-derived xenograft (CDX) in vivo, and we successfully constructed three BL patient-derived xenograft (PDX) models, and found that VPA had significant inhibitory effects on BL PDX models in vitro and in vivo. Finally, we used RNA-seq, qPCR and Western blotting to verify that VPA could inhibit the growth of BL by down-regulating PFN2 and inhibiting PI3K/AKT pathway. In conclusion, our study demonstrated that VPA was a promising candidate for BL treatment by inhibiting PFN2/PI3K/AKT pathway.

ORGANISM(S): Mus musculus

PROVIDER: GSE298448 | GEO | 2025/06/03

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Histone deacetylation is crucial for the regulation of chromatin structure, gene transcription and the epigenetic state of the cell. With the emergence of the neuroendocrine (NE) phenotype in castration-resistant prostate cancer (CRPC), we hypothesized that the inhibition of HDAC1/2 would disrupt the epigenetic events involved in the conversion of prostate adenocarcinoma to a NE prostate cancer (NEPC) phenotype. Additionally, monotherapies tend to have limited efficacy in cancer treatment and combination treatments show more promise. Since the PI3K/AKT/mTOR pathway is a well-established tumor growth-promoting pathway and a promising target in CRPC and NEPC, we investigated the tumor suppressing activities of fimepinostat, a dual HDAC and PI3K inhibitor, on both prostate adenocarcinoma and NEPC. We evaluated multiple cell lines and patient-derived xenograft (PDX) models of prostate adenocarcinoma and NEPC to determine the roles of HDAC1/2 and AKT inhibition, both individually and in combination, in suppressing CRPC and NEPC tumor growth in vitro and in vivo. HDAC1/2 inhibition in combination with PI3K/AKT inhibition was more efficacious than targeting each pathway alone, induced growth inhibitory effects (in some cases synergistic) through cell cycle inhibition and apoptosis across an array of prostate adenocarcinoma and NEPC patient-derived xenografts (PDX) and cell lines in vitro and in vivo. Molecular profiling revealed on-target effects of combined HDAC1/2 and PI3K/AKT inhibition as well as a common downregulation of Myc, E2F, DNA repair, and G2M checkpoint targets, independent of prostate cancer phenotype. Fimepinostat therapy was also associated with the suppression of lineage transcription factor expression including androgen receptor (AR) in prostate adenocarcinoma and Achaete-scute homolog 1 (ASCL1) in NEPC. Our findings demonstrate that dual HDAC1/2 and PI3K/AKT pathway inhibition leads to robust tumor growth inhibition in both adenocarcinoma and NEPC, suggesting that fimepinostat may represent a novel therapeutic for both prostate adenocarcinoma and NEPC phenotypes of CRPC.

Dataset Information

Valproic acid inhibits Burkitt lymphoma by downregulating PFN2 expression to modulate the PI3K/AKT pathway

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets